시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 갑상선 안병증(TED) 시장 보고서(2025년)
Thyroid Eye Disease (TED) Global Market Report 2025
상품코드 : 1720907
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,310,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,121,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,932,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

갑상선 안병증(TED) 시장 규모는 앞으로 수 년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.6%로 29억 7,000만 달러로 성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 바세도우 병 유병률 증가, 다양한 산업에서의 자금 조달 증가, 헬스케어 지출 증가, 갑상선 호르몬 보충 요법의 이용 확대, 갑상선 질환의 이환율의 상승에 의해 견인될 가능성이 있습니다. 이 기간의 주요 동향에는 기술 발전, 연구 개발 활동 확대, 신약 개발, 치료 옵션 개선, 새로운 수술 절차 도입 등이 있습니다.

갑상선 질환의 유병률 증가는 갑상선 안병증(TED) 시장의 확대를 촉진할 것으로 예측됩니다. 갑상선 질환은 갑상선의 기능을 방해하여 호르몬 불균형이나 갑상선 기능 저하증, 갑상선 기능 항진증, 갑상선종, 갑상선 안병증 등의 상태를 일으키는 병리입니다. 갑상선 질환의 이환율 증가는 요오드 섭취량 증가, 자가면역 질환, 유전적 소인, 진단률의 향상으로 이어지는 인지도의 향상 등의 요인에 기인합니다. 갑상선 안병증(TED)은 바세도우병의 심각하고 일반적인 합병증이기 때문에 갑상선 질환의 사례 수를 증가시키는데 중요한 역할을 하고 있으며, 갑상선 관련 질환의 전반적인 부담과 인지도 향상에 기여하고 있습니다. 예를 들어 2024년 5월 캐나다를 거점으로 하는 비영리단체인 캐나다암협회는 2024년 캐나다에서 기본 추정 6,600 건의 갑상선암이 새롭게 진단될 것으로 예상되며, 약 280건의 사망이 예측된다고 보고했습니다. 그 결과, 갑상선 질환의 유병률 증가로 갑상선 안병증(TED) 시장 성장이 촉진되고 있습니다.

갑상선 안병증(TED) 시장의 주요 기업은 단일클론항체 요법과 같은 혁신적인 치료법의 개발을 선호하고, 염증을 억제하고, 눈꺼풀 뇌하수를 개선하고, 환자의 결과 전체를 향상시키는 보다 효과적이고 적극적인 솔루션을 제공합니다. 신체 요법은 특정 병원체와 비정상적인 세포를 인식하고 중화하는 면역계의 능력을 모방하도록 설계된 실험실에서 조작된 항체를 포함합니다. 위협할 수 있는 희귀한 자가면역 질환인 활동성 갑상선 안병증(TED)의 치료로서 TEPEZZA (teprotumumab)를 승인했다고 발표했습니다. 테페자(TEPEZA)는 TED에 특화된 최초이자 유일한 FDA 승인 치료제로, 염증, 부기 및 기타 쇠약해지는 증상을 줄이는 데 도움이 되는 표적 치료제를 제공합니다

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Thyroid eye disease (TED), also known as Graves' Orbitopathy, is an autoimmune disorder marked by inflammation and swelling of the tissues surrounding the eyes, often linked to thyroid conditions. TED can lead to symptoms such as bulging eyes, double vision, and eye discomfort.

The primary treatment approaches for TED include medical, surgical, and a combination of both. Medical management typically involves corticosteroids, immunosuppressive drugs, and biologic therapies to reduce inflammation, alleviate symptoms, and prevent disease progression. Treatment is customized based on disease severity, classified into mild, moderate, and severe stages. The drugs used belong to various categories, including biologics, small molecules, and others. They are administered through different routes, such as oral, intravenous, and subcutaneous methods, and are utilized by various end users, including hospitals, clinics, and other healthcare facilities.

The thyroid eye disease (TED) market research report is one of a series of new reports from The Business Research Company that provides thyroid eye disease (TED) market statistics, including the thyroid eye disease (TED) industry global market size, regional shares, competitors with the thyroid eye disease (TED) market share, detailed thyroid eye disease (TED) market segments, market trends, and opportunities, and any further data you may need to thrive in the thyroid eye disease (TED) industry. This thyroid eye disease (TED) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The thyroid eye disease (TED) market size has grown strongly in recent years. It will grow from $2.15 billion in 2024 to $2.30 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to the rising incidence of thyroid disorders, a growing emphasis on patient-centered care, increasing demand for cosmetic procedures, a higher prevalence of the disease, and the expansion of treatment options for TED.

The thyroid eye disease (TED) market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be driven by the rising prevalence of Graves' disease, increased funding across various industries, growing healthcare expenditure, greater use of thyroid hormone replacement therapy, and a higher incidence of thyroid disease. Key trends in this period include technological advancements, expanding R&D activities, the development of novel drugs, improvements in treatment options, and the introduction of new surgical techniques.

The increasing prevalence of thyroid disorders is expected to drive the expansion of the thyroid eye disease (TED) market. Thyroid disorders are medical conditions that disrupt the function of the thyroid gland, leading to hormonal imbalances and conditions such as hypothyroidism, hyperthyroidism, goiter, and thyroid eye disease. The rising incidence of thyroid disorders is attributed to factors such as increased iodine intake, autoimmune diseases, genetic predisposition, and improved awareness leading to higher diagnostic rates. Thyroid Eye Disease (TED) plays a significant role in the growing number of thyroid disorder cases, as it is a serious and common complication of Graves' disease, contributing to the overall burden and awareness of thyroid-related conditions. For example, in May 2024, the Canadian Cancer Society, a Canada-based non-profit organization, reported that an estimated 6,600 new cases of thyroid cancer are expected to be diagnosed in Canada in 2024, with approximately 280 projected fatalities. As a result, the increasing prevalence of thyroid disorders is fueling the growth of the thyroid eye disease (TED) market.

Leading companies in the thyroid eye disease (TED) market are prioritizing the development of innovative treatments, such as monoclonal antibody therapies, to provide more effective, targeted solutions that reduce inflammation, improve proptosis, and enhance overall patient outcomes. Monoclonal antibody therapies involve laboratory-engineered antibodies designed to mimic the immune system's ability to recognize and neutralize specific pathogens or abnormal cells. For instance, in September 2024, Amgen Inc., a US-based biotechnology company, announced that Japan's Ministry of Health, Labour and Welfare (MHLW) had approved TEPEZZA (teprotumumab) for the treatment of active thyroid eye disease (TED), a rare and potentially vision-threatening autoimmune disorder. TEPEZZA is the first and only FDA-approved therapy specifically for TED, offering a targeted treatment that helps reduce inflammation, swelling, and other debilitating symptoms associated with the disease. This approval is particularly significant for patients in Japan, as it introduces an effective new option for managing TED, a progressive condition that can cause severe eye bulging, vision impairment, and eye pain.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for an undisclosed amount. This acquisition strengthens Amgen's rare and inflammatory disease portfolio by integrating Horizon's key therapies, expanding its global reach, and driving innovation for long-term growth. Horizon Therapeutics plc, an Ireland-based company, specializes in treatments for rare autoimmune and inflammatory diseases.

Major players in the thyroid eye disease (ted) market are Hoffmann-La Roche AG, Amgen Inc., Genentech Inc., Horizon Therapeutics plc, Pierre Fabre S.A., Innovent Biologics Inc., ACELYRIN Inc., Soleo Health, Zai Lab Limited, HanAll Biopharma Co. Ltd., Tourmaline Bio Inc., Zenas BioPharma Inc., Immunovant Inc., Verana Health, Harbour BioMed (Guangzhou) Co. Ltd., Sling Therapeutics Inc., Crinetics Pharmaceuticals Inc., Lassen Therapeutics Inc., Viridian Therapeutics Inc., Minghui Pharmaceutical Inc.

North America was the largest region in the thyroid eye disease (TED) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thyroid eye disease (TED) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the thyroid eye disease (TED) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thyroid eye disease (TED) market includes revenues earned by entities by providing services such as diagnosis services, pharmaceutical services, surgical services, support, and counseling services and related products including thyroid hormone replacement therapy, immunosuppressive drugs, surgical products, and devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thyroid Eye Disease (TED) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on thyroid eye disease (ted) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for thyroid eye disease (ted) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The thyroid eye disease (ted) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Thyroid Eye Disease (TED) Market Characteristics

3. Thyroid Eye Disease (TED) Market Trends And Strategies

4. Thyroid Eye Disease (TED) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Thyroid Eye Disease (TED) Growth Analysis And Strategic Analysis Framework

6. Thyroid Eye Disease (TED) Market Segmentation

7. Thyroid Eye Disease (TED) Market Regional And Country Analysis

8. Asia-Pacific Thyroid Eye Disease (TED) Market

9. China Thyroid Eye Disease (TED) Market

10. India Thyroid Eye Disease (TED) Market

11. Japan Thyroid Eye Disease (TED) Market

12. Australia Thyroid Eye Disease (TED) Market

13. Indonesia Thyroid Eye Disease (TED) Market

14. South Korea Thyroid Eye Disease (TED) Market

15. Western Europe Thyroid Eye Disease (TED) Market

16. UK Thyroid Eye Disease (TED) Market

17. Germany Thyroid Eye Disease (TED) Market

18. France Thyroid Eye Disease (TED) Market

19. Italy Thyroid Eye Disease (TED) Market

20. Spain Thyroid Eye Disease (TED) Market

21. Eastern Europe Thyroid Eye Disease (TED) Market

22. Russia Thyroid Eye Disease (TED) Market

23. North America Thyroid Eye Disease (TED) Market

24. USA Thyroid Eye Disease (TED) Market

25. Canada Thyroid Eye Disease (TED) Market

26. South America Thyroid Eye Disease (TED) Market

27. Brazil Thyroid Eye Disease (TED) Market

28. Middle East Thyroid Eye Disease (TED) Market

29. Africa Thyroid Eye Disease (TED) Market

30. Thyroid Eye Disease (TED) Market Competitive Landscape And Company Profiles

31. Thyroid Eye Disease (TED) Market Other Major And Innovative Companies

32. Global Thyroid Eye Disease (TED) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Thyroid Eye Disease (TED) Market

34. Recent Developments In The Thyroid Eye Disease (TED) Market

35. Thyroid Eye Disease (TED) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기